DK2513119T3 - 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinolin derivater - Google Patents

3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinolin derivater

Info

Publication number
DK2513119T3
DK2513119T3 DK10790569.7T DK10790569T DK2513119T3 DK 2513119 T3 DK2513119 T3 DK 2513119T3 DK 10790569 T DK10790569 T DK 10790569T DK 2513119 T3 DK2513119 T3 DK 2513119T3
Authority
DK
Denmark
Prior art keywords
thiopyrano
derivates
isoquinoline
tetrahydro
isoquinoline derivates
Prior art date
Application number
DK10790569.7T
Other languages
Danish (da)
English (en)
Inventor
Clemens Braun
Thomas Stengel
Hermann Tenor
Raimund Külzer
Christof Zitt
Armin Hatzelmann
Christian Hesslinger
Thomas Maier
Degenhard Marx
Dieter Flockerzi
Alexander Mann
Harald Ohmer
Ulrich Kautz
Steffen Weinbrenner
Stefan Fischer
Torsten Dunkern
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Application granted granted Critical
Publication of DK2513119T3 publication Critical patent/DK2513119T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
DK10790569.7T 2009-12-18 2010-12-15 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinolin derivater DK2513119T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09179982 2009-12-18
US31555210P 2010-03-19 2010-03-19
PCT/EP2010/069704 WO2011073231A1 (en) 2009-12-18 2010-12-15 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES

Publications (1)

Publication Number Publication Date
DK2513119T3 true DK2513119T3 (da) 2014-10-06

Family

ID=41718903

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10790569.7T DK2513119T3 (da) 2009-12-18 2010-12-15 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinolin derivater

Country Status (29)

Country Link
US (1) US9018175B2 (enExample)
EP (2) EP2813509B1 (enExample)
JP (1) JP5645961B2 (enExample)
KR (1) KR20120123313A (enExample)
CN (1) CN102652136B (enExample)
AR (1) AR079451A1 (enExample)
AU (1) AU2010332955B8 (enExample)
BR (1) BR112012014058A8 (enExample)
CA (1) CA2784013A1 (enExample)
CO (1) CO6551705A2 (enExample)
DK (1) DK2513119T3 (enExample)
EA (1) EA023212B1 (enExample)
ES (2) ES2621291T3 (enExample)
GE (1) GEP20146105B (enExample)
HR (1) HRP20140893T1 (enExample)
ME (1) ME01914B (enExample)
MX (1) MX2012006696A (enExample)
NZ (1) NZ601115A (enExample)
PH (1) PH12012501125A1 (enExample)
PL (1) PL2513119T3 (enExample)
PT (1) PT2513119E (enExample)
RS (1) RS53544B1 (enExample)
SG (2) SG196785A1 (enExample)
SI (1) SI2513119T1 (enExample)
SM (1) SMT201400185B (enExample)
TW (1) TWI468411B (enExample)
UA (1) UA107689C2 (enExample)
WO (1) WO2011073231A1 (enExample)
ZA (1) ZA201204135B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300432A1 (en) 2010-06-07 2011-12-08 Snyder Shawn W Rechargeable, High-Density Electrochemical Device
WO2012110770A2 (en) * 2011-02-17 2012-08-23 Cipla Limited Pharmaceutical composition
JP2014519519A (ja) * 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規3,4,4a,10b−テトラヒドロ−1H−チオピラノ[4,3−c]イソキノリン化合物
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
US20150322049A1 (en) * 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
MX2015009678A (es) 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
DE2047465A1 (de) 1970-09-26 1972-03-30 Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt Neue Oxdiazole und Verfahren zu lh rer Herstellung
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
JPH01213284A (ja) 1988-02-22 1989-08-28 Sankyo Co Ltd チエノピリミジン−2,4−ジオン誘導体
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE407028T1 (de) 1989-05-31 1994-03-17 Fisons Plc Medikament und Inhalationsvorrichtung dafür.
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
JPH05505824A (ja) 1990-03-23 1993-08-26 ミネソタ マイニング アンド マニュファクチャリング カンパニー 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用
ATE114112T1 (de) 1990-10-18 1994-12-15 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
IL111194A (en) 1993-10-08 1998-02-08 Fisons Plc Process for the production of medicament formulations
DK0937074T3 (da) 1996-11-11 2003-06-23 Altana Pharma Ag Benzonaphthyridiner som bronkiale terapeutiske midler
WO1998050385A1 (en) 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
AU8106598A (en) 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
ATE234604T1 (de) 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
EP1194244B1 (en) 1999-04-23 2005-12-21 Battelle Memorial Institute Directionally controlled ehd aerosol sprayer
DE60030103T2 (de) 1999-04-23 2007-02-08 Ventaira Pharmaceuticals, Inc., Columbus Elektrostatisches versprühen mit transfer- hoher masse
EP1227084B1 (en) 1999-10-28 2005-12-14 Trine Pharmaceuticals, Inc. Drug discharge pump inhibitors
CA2411013A1 (en) 2000-06-07 2001-12-13 Jose Manuel Prieto Soto 6-phenylpyrrolopyrimidinedione derivatives
WO2002005616A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
CN1635870A (zh) 2000-10-09 2005-07-06 3M创新有限公司 药用气雾剂制剂
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
CA2563377A1 (en) 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
US7589205B2 (en) 2004-09-08 2009-09-15 Nycomed Gmbh 3-thia-10-aza-phenanthrene derivatives
DE602005027866D1 (de) * 2004-09-08 2011-06-16 Nycomed Gmbh 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren
CA2588768A1 (en) 2004-11-17 2006-05-26 Kissei Pharmaceutical Co., Ltd. Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
AU2006221957A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
JP2014519519A (ja) * 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規3,4,4a,10b−テトラヒドロ−1H−チオピラノ[4,3−c]イソキノリン化合物

Also Published As

Publication number Publication date
ME01914B (me) 2015-05-20
SMT201400185B (it) 2015-01-15
BR112012014058A2 (pt) 2017-10-24
EP2513119A1 (en) 2012-10-24
HK1174326A1 (en) 2013-06-07
CA2784013A1 (en) 2011-06-23
PL2513119T3 (pl) 2014-11-28
AU2010332955A1 (en) 2012-08-02
ZA201204135B (en) 2013-03-27
SG196785A1 (en) 2014-02-13
AU2010332955A8 (en) 2015-05-28
US9018175B2 (en) 2015-04-28
EP2813509B1 (en) 2017-02-01
CN102652136A (zh) 2012-08-29
BR112012014058A8 (pt) 2018-02-06
TWI468411B (zh) 2015-01-11
AU2010332955B8 (en) 2015-05-21
EA201200891A1 (ru) 2013-01-30
EP2513119B1 (en) 2014-06-25
GEP20146105B (en) 2014-05-27
WO2011073231A1 (en) 2011-06-23
CN102652136B (zh) 2014-11-26
KR20120123313A (ko) 2012-11-08
HRP20140893T1 (hr) 2014-11-07
JP5645961B2 (ja) 2014-12-24
ES2621291T3 (es) 2017-07-03
SI2513119T1 (sl) 2014-10-30
EP2813509A1 (en) 2014-12-17
NZ601115A (en) 2014-05-30
TW201130851A (en) 2011-09-16
ES2505290T3 (es) 2014-10-09
CO6551705A2 (es) 2012-10-31
AU2010332955B2 (en) 2015-01-22
AR079451A1 (es) 2012-01-25
MX2012006696A (es) 2012-07-17
SG180824A1 (en) 2012-07-30
EA023212B1 (ru) 2016-05-31
PT2513119E (pt) 2014-09-05
PH12012501125A1 (en) 2012-10-29
JP2013514308A (ja) 2013-04-25
UA107689C2 (xx) 2015-02-10
US20120289474A1 (en) 2012-11-15
RS53544B1 (sr) 2015-02-27

Similar Documents

Publication Publication Date Title
BRPI0914657A2 (pt) piridin-2-onae piridazin-3-onas substituídas
ZA201007126B (en) Isoquinolinone derivatives as nk3 antagonists
BR112012014058A2 (pt) derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
BRPI1011683A2 (pt) derivado isoquinolina substituída
DK2276486T3 (da) Nye substituerede imidazo-quinoliner
BRPI0908050A2 (pt) Furo-e tieno[3,2-c]piridinas
EP2257169A4 (en) TETRAHYDROTHIENPYRIDINE
ZA201104421B (en) Isoquinoline derivative
EP2231155A4 (en) Tetrahydroisoquinoline DERIVATIVES
ZA201103119B (en) Isoquinolinone derivatives as nk3 antagonists
PT2657227T (pt) Novo derivado de isoquinolina substituída
IL212107A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL209663A0 (en) Isoquinolinone derivatives as nk3 antagonists
ZA201006563B (en) Novel tetrahydroisoquinoline derivative
IL216062A0 (en) Novel isoquinoline derivatives
GB2476643B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
EP2586772A4 (en) isoquinoline
EP2344472A4 (en) ISOCHINOLINONDERIVATE
TH96521B (th) ลวดลายบนถ้วย
IL201721A0 (en) Isoquinolinone derivatives as nk3 antagonists
FI20086003A0 (fi) Lukittava panta
GB0913095D0 (en) Fair-teez or derivitive thereof
GB0814640D0 (en) Alarm
TH96516B (th) ลวดลายบนถ้วย